- Home
- MHN vs CADL Comparison
MHN vs CADL Comparison
Compare MHN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.80
Company Overview
Basic Information| Metric | MHN | CADL |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.6M | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MHN | CADL |
|---|---|---|
| Price | $10.22 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 59.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.69 | $4.25 |
| 52 Week High | $10.81 | $13.68 |
Technical Indicators
Market Signals| Indicator | MHN | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 57.46 |
| Support Level | $10.21 | $5.45 |
| Resistance Level | $10.34 | $6.14 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 4.17 | 45.28 |
Price Performance
Historical Comparison MHN
CADL
About MHN Blackrock MuniHoldings New York Quality Fund Inc.
BLACKROCK MUNIHOLDINGS NEW YORK QUALITY FUND, INC. is a closed-ended management investment company. The fund's investment objective is to provide shareholders with current income exempt from federal income tax and New York State and New York City personal income taxes.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.